Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Jerusalem

Showing results (1-10 of 178) with videos related to

Pageof 18
Sort By:
Breast Cancer : Basic and Clinical Research|January 19, 2017
Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast CancerLaurence Lousberg, Guy Jerusalem
La Revue Du Praticien|December 24, 2003
[Positron emission tomography: a revolution in oncology?]Guy Jerusalem, Roland Hustinx
Haematologica|April 6, 2006
The place of positron emission tomography imaging in the management of patients with malignant lymphomaGuy Jerusalem, Yves Beguin
Gland Surgery|March 21, 2025
Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer presenting <i>gBRCA1/2</i> mutations?Pierre Foidart, Guy Jerusalem
Expert Review of Anticancer Therapy|November 25, 2020
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysisConcetta E Onesti, Guy Jerusalem
Methods in Molecular Medicine|May 25, 2005
Metabolic monitoring of chemosensitivity with 18FDG PETGuy Jerusalem, Tarik Z Belhocine
The New England Journal of Medicine|June 4, 2020
Ribociclib plus Fulvestrant in Advanced Breast Cancer. ReplyDennis J Slamon, Guy Jerusalem
Expert Review of Pharmacoeconomics & Outcomes Research|August 19, 2014
The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspectiveShaloo Gupta, Jie Zhang, Guy Jerusalem
Breast Cancer (Dove Medical Press)|May 17, 2014
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomesGuy Jerusalem, Andree Rorive, Joelle Collignon
Therapeutic Advances in Medical Oncology|November 2, 2016
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesLaurence Lousberg, Joëlle Collignon, Guy Jerusalem
Pageof 18

Showing results (1-10 of 178) with videos related to

Sort By:
Pageof 18
Breast Cancer : Basic and Clinical Research|January 19, 2017
Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast CancerLaurence Lousberg, Guy Jerusalem
La Revue Du Praticien|December 24, 2003
[Positron emission tomography: a revolution in oncology?]Guy Jerusalem, Roland Hustinx
Haematologica|April 6, 2006
The place of positron emission tomography imaging in the management of patients with malignant lymphomaGuy Jerusalem, Yves Beguin
Gland Surgery|March 21, 2025
Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer presenting <i>gBRCA1/2</i> mutations?Pierre Foidart, Guy Jerusalem
Expert Review of Anticancer Therapy|November 25, 2020
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysisConcetta E Onesti, Guy Jerusalem
Methods in Molecular Medicine|May 25, 2005
Metabolic monitoring of chemosensitivity with 18FDG PETGuy Jerusalem, Tarik Z Belhocine
The New England Journal of Medicine|June 4, 2020
Ribociclib plus Fulvestrant in Advanced Breast Cancer. ReplyDennis J Slamon, Guy Jerusalem
Expert Review of Pharmacoeconomics & Outcomes Research|August 19, 2014
The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspectiveShaloo Gupta, Jie Zhang, Guy Jerusalem
Breast Cancer (Dove Medical Press)|May 17, 2014
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomesGuy Jerusalem, Andree Rorive, Joelle Collignon
Therapeutic Advances in Medical Oncology|November 2, 2016
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesLaurence Lousberg, Joëlle Collignon, Guy Jerusalem
Pageof 18